PL3039038T3 - Konstrukt fuzyjny z fab przeciwko albuminie surowicy i ugrupowania efektorowego oraz sposób jego przygotowania - Google Patents

Konstrukt fuzyjny z fab przeciwko albuminie surowicy i ugrupowania efektorowego oraz sposób jego przygotowania

Info

Publication number
PL3039038T3
PL3039038T3 PL14839630T PL14839630T PL3039038T3 PL 3039038 T3 PL3039038 T3 PL 3039038T3 PL 14839630 T PL14839630 T PL 14839630T PL 14839630 T PL14839630 T PL 14839630T PL 3039038 T3 PL3039038 T3 PL 3039038T3
Authority
PL
Poland
Prior art keywords
serum albumin
preparing method
fusion construct
effector moiety
anti serum
Prior art date
Application number
PL14839630T
Other languages
English (en)
Inventor
Sanghoon Cha
Original Assignee
Aprilbio Co., Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aprilbio Co., Ltd filed Critical Aprilbio Co., Ltd
Publication of PL3039038T3 publication Critical patent/PL3039038T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/565—IFN-beta
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/61—Growth hormone [GH], i.e. somatotropin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C07K14/765—Serum albumin, e.g. HSA
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/35—Fusion polypeptide containing a fusion for enhanced stability/folding during expression, e.g. fusions with chaperones or thioredoxin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
PL14839630T 2013-08-30 2014-08-29 Konstrukt fuzyjny z fab przeciwko albuminie surowicy i ugrupowania efektorowego oraz sposób jego przygotowania PL3039038T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR20130104112 2013-08-30
EP14839630.2A EP3039038B1 (en) 2013-08-30 2014-08-29 An anti serum albumin fab-effector moiety fusion construct, and the preparing method thereof
PCT/KR2014/008106 WO2015030539A1 (en) 2013-08-30 2014-08-29 An anti serum albumin fab-effector moiety fusion construct, and the preparing method thereof

Publications (1)

Publication Number Publication Date
PL3039038T3 true PL3039038T3 (pl) 2021-04-19

Family

ID=52586989

Family Applications (1)

Application Number Title Priority Date Filing Date
PL14839630T PL3039038T3 (pl) 2013-08-30 2014-08-29 Konstrukt fuzyjny z fab przeciwko albuminie surowicy i ugrupowania efektorowego oraz sposób jego przygotowania

Country Status (17)

Country Link
US (2) US9879077B2 (pl)
EP (2) EP3039038B1 (pl)
JP (2) JP6422977B2 (pl)
KR (2) KR101576561B1 (pl)
CN (1) CN105899532B (pl)
AU (1) AU2014312456B2 (pl)
BR (1) BR112016004355A2 (pl)
CA (1) CA2922618C (pl)
DK (1) DK3039038T3 (pl)
ES (1) ES2866848T3 (pl)
HK (1) HK1223107A1 (pl)
MX (1) MX371328B (pl)
PH (1) PH12016500403A1 (pl)
PL (1) PL3039038T3 (pl)
RU (1) RU2661087C2 (pl)
UA (1) UA117493C2 (pl)
WO (1) WO2015030539A1 (pl)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108623691B (zh) * 2017-03-17 2020-05-15 北京比洋生物技术有限公司 IgG样长效免疫融合蛋白及其应用
JP2021527706A (ja) * 2018-06-18 2021-10-14 アンウィタ バイオサイエンシス， インク． 抗メソテリンコンストラクト及びその使用
KR20210095781A (ko) 2020-01-24 2021-08-03 주식회사 에이프릴바이오 항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물
KR102485892B1 (ko) * 2020-04-09 2023-01-09 주식회사 에이프릴바이오 고양이 과립구 집락 자극인자 및 혈청 알부민에 대한 항원 결합 단편을 포함하는 융합 단백질 및 이의 용도
KR20220044057A (ko) * 2020-09-29 2022-04-06 주식회사 에이프릴바이오 인터루킨-18 결합 단백질 및 혈청 알부민에 대한 항원 결합 단편을 포함하는 융합 단백질, 및 이의 용도
WO2023242251A1 (en) * 2022-06-15 2023-12-21 UCB Biopharma SRL Follistatin-fc fusion proteins
KR20240048577A (ko) * 2022-10-04 2024-04-16 주식회사 에이프릴바이오 난포자극 호르몬 및 혈청 알부민에 대한 항원 결합 단편을 포함하는 융합 단백질 및 이의 용도

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW517061B (en) * 1996-03-29 2003-01-11 Pharmacia & Amp Upjohn Ab Modified/chimeric superantigens and their use
PT1517921E (pt) * 2002-06-28 2006-09-29 Domantis Ltd Ligandos duplamente especificos com semi-vida no soro aumentada
US9321832B2 (en) * 2002-06-28 2016-04-26 Domantis Limited Ligand
GB0315450D0 (en) * 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
CN101031588A (zh) * 2004-06-01 2007-09-05 多曼蒂斯有限公司 药物组合物，融合物和结合物
KR20120133403A (ko) * 2004-06-01 2012-12-10 도만티스 리미티드 증강된 혈청 반감기를 가지는 이특이성 융합 항체
US20080181892A1 (en) * 2004-08-11 2008-07-31 Trubion Pharmaceuticals Binding Domain Fusion Protein
WO2006041641A2 (en) * 2004-10-05 2006-04-20 Genentech, Inc. Therapeutic agents with decreased toxicity
WO2006059110A2 (en) * 2004-12-02 2006-06-08 Domantis Limited Plad domain peptides with increased serum half life due to conjugation to domain antibodies
WO2006085518A1 (ja) * 2005-02-08 2006-08-17 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute 抗体の改良方法
CA2689556A1 (en) * 2007-06-08 2008-12-11 Dow Global Technolgies Inc. Expression of soluble antibody fragment by truncation of ch1 domain
EP2535351A3 (en) * 2007-09-26 2013-04-03 UCB Pharma S.A. Dual specificity antibody fusions
CA2721093A1 (en) * 2008-04-11 2009-10-15 Merrimack Pharmaceuticals, Inc. Human serum albumin linkers and conjugates thereof
JP6063122B2 (ja) * 2008-09-26 2017-01-18 ユセベ ファルマ ソシエテ アノニム 生物学的産物
MX2011005874A (es) * 2008-12-05 2011-06-27 Glaxo Group Ltd Metodos para seleccionar polipeptidos resistentes a proteasa.
CN102612376A (zh) * 2009-08-06 2012-07-25 诺沃-诺迪斯克保健股份有限公司 具有延长的体内功效的生长激素
GB201005063D0 (en) * 2010-03-25 2010-05-12 Ucb Pharma Sa Biological products
AU2010303112A1 (en) * 2009-09-30 2012-04-26 Glaxo Group Limited Drug fusions and conjugates with extended half life
CN103842383B (zh) * 2011-05-16 2017-11-03 健能隆医药技术（上海）有限公司 多特异性fab融合蛋白及其使用方法
EP2776466B1 (en) * 2011-11-11 2017-08-23 UCB Biopharma SPRL Albumin binding antibodies and binding fragments thereof

Also Published As

Publication number Publication date
KR20150026997A (ko) 2015-03-11
US9879077B2 (en) 2018-01-30
EP3039038A1 (en) 2016-07-06
EP3632930A1 (en) 2020-04-08
KR20150118565A (ko) 2015-10-22
US10618953B2 (en) 2020-04-14
CN105899532A (zh) 2016-08-24
WO2015030539A1 (en) 2015-03-05
CA2922618A1 (en) 2015-03-05
AU2014312456A1 (en) 2016-03-03
RU2661087C2 (ru) 2018-07-11
US20180030127A1 (en) 2018-02-01
BR112016004355A2 (pt) 2017-10-17
JP6800180B2 (ja) 2020-12-16
MX2016002539A (es) 2016-10-13
JP2018172391A (ja) 2018-11-08
ES2866848T3 (es) 2021-10-19
EP3039038A4 (en) 2017-07-05
CN105899532B (zh) 2021-10-08
MX371328B (es) 2020-01-27
HK1223107A1 (zh) 2017-07-21
AU2014312456A8 (en) 2016-03-17
RU2016105586A (ru) 2017-10-04
JP2016528922A (ja) 2016-09-23
DK3039038T3 (da) 2021-02-08
UA117493C2 (uk) 2018-08-10
AU2014312456B2 (en) 2017-07-06
CA2922618C (en) 2020-04-28
KR101576561B1 (ko) 2015-12-10
JP6422977B2 (ja) 2018-11-14
US20160376350A1 (en) 2016-12-29
EP3039038B1 (en) 2020-11-25
PH12016500403A1 (en) 2016-05-16

Similar Documents

Publication Publication Date Title
HK1225596A1 (zh) 吸收複合物、採用該吸收複合物的吸收製品、以及製造該吸收複合物和/或製品的方法、系統和裝置
HK1208476A1 (en) Anti-b7-h6 antibody, fusion proteins, and methods of using the same b7-h6
EP2943512A4 (en) FUSION BOVINE ANTIBODIES
IL245132B (en) Composite material, heat absorbing component and method for manufacturing the composite material
HK1223107A1 (zh) 抗血清白蛋白的 -效應物部分的融合構建體及其製備方法
SG10201407632UA (en) Transducer and method for forming the same
EP2968551A4 (en) FUSION PROTEINS AND METHOD THEREFOR
SG11201601777RA (en) Sliced assembly type container and method for manufacturing the same
IL240665A0 (en) Improved aluminum-magnesium-lithium alloys and methods for their production
IL244043B (en) Antibodies against CSF-1r and their use.
HRP20190434T1 (hr) Fuzijski protein
GB201419614D0 (en) Magnetic core element, magnetic core module and an inductive component using the magnetic core module
PL2983012T3 (pl) Wieloenergetyczny wielodawkowy akcelerator, szybki układ kontrolny mający akcelerator i odpowiedni szybki sposób kontrolowania
EP3017149A4 (en) WEARING SURFACE AND METHOD FOR MANUFACTURING THE SAME
EP3089951A4 (en) Ceramic and method for preparing the same
HK1220903A1 (zh) 軟骨結合型融合蛋白
EP3087010A4 (en) Container closure, container assembly and method for utilizing the same
EP3065774A4 (en) Anti-ccl17 antibodies
EP3041383A4 (en) Cover member and method for manufacturing the same
HK1214414A1 (zh) 連接裝置及其組件和組裝方法
EP3052484A4 (en) Sulfonylindole derivatives and method for preparing the same
GB201305195D0 (en) Barrier system and ,ethod of assembling the same
EP2961427A4 (en) HIV ANTIGENS AND ANTIBODIES AGAINST HIV ANTIGENS
IL242217B (en) A method to assist in searching for an element, and related device and vehicles
GB201318660D0 (en) Ferritic alloys and methods for preparing the same